Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Douglas M. Hunt Sells 3,443 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Douglas M. Hunt sold 3,443 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $3.54, for a total transaction of $12,188.22. Following the sale, the insider owned 164,894 shares of the company's stock, valued at $583,724.76. This represents a 2.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Puma Biotechnology Price Performance

PBYI traded down $0.13 on Friday, hitting $3.39. 300,719 shares of the company were exchanged, compared to its average volume of 414,487. Puma Biotechnology, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $4.13. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. The firm has a market capitalization of $168.25 million, a P/E ratio of 4.40 and a beta of 1.29. The business's fifty day moving average is $3.37 and its 200 day moving average is $3.18.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its stake in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 6,351 shares in the last quarter. Graham Capital Management L.P. purchased a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $33,000. ProShare Advisors LLC purchased a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $36,000. C2C Wealth Management LLC purchased a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $37,000. Finally, Causeway Capital Management LLC purchased a new position in shares of Puma Biotechnology during the 1st quarter worth approximately $42,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.